Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.9% during the second quarter, Holdings Channel reports. The institutional investor owned 9,576 shares of the biopharmaceutical company’s stock after selling 1,424 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Regeneron Pharmaceuticals were worth $5,971,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. WPG Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the period. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth approximately $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target to $1,030 from $1,000 and maintained a “buy” rating, implying substantial upside based on confidence in Regeneron’s long-term pipeline and business prospects. Guggenheim price-target report
• Positive Sentiment: Regeneron’s recent quarterly performance provides fundamental support: earnings and revenue exceeded consensus estimates, with revenue up 16.7% year over year. Zacks also identified REGN as a highly ranked value stock. Zacks value-stock analysis
• Neutral Sentiment: Citigroup raised its price target to $740 from $700 but retained a “neutral” rating, indicating limited near-term upside at the referenced valuation and a cautious view of the company’s outlook. Citigroup price-target report
• Negative Sentiment: The major adverse catalyst is the reported failure of the Phase 3 Fianlimab-Libtayo trial in melanoma. Disclosures involving a protocol change and failure to meet the primary endpoint reportedly challenged earlier positive trial-risk messaging and caused a roughly 9%–10% selloff, erasing about $11 billion in market value. Regeneron clinical-trial and lawsuit report
• Negative Sentiment: Several law firms announced or promoted securities-fraud class actions alleging Regeneron and certain executives misled investors during the August 1, 2025–May 15, 2026 class period. The repeated notices increase legal and reputational uncertainty; September 14, 2026 is cited as the lead-plaintiff deadline. Regeneron shareholder-alert report
• Negative Sentiment: Biocon launched Yesafili, a U.S. biosimilar to Regeneron’s Eylea 2 mg. Increased competition could pressure pricing and sales from one of Regeneron’s important products. Biocon Yesafili launch

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Citigroup raised their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research note on Monday. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Leerink Partners reiterated a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $797.75.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $760.66 on Wednesday. The firm’s 50 day simple moving average is $648.06 and its 200-day simple moving average is $711.36. The company has a market cap of $80.42 billion, a P/E ratio of 18.80, a price-to-earnings-growth ratio of 1.49 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the business earned $12.81 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.64 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.